BACKGROUND: Omega-3 fatty acid (n-3 FA) blood levels and intake have been inversely associated with risk for sudden cardiac death, but their relationship with all-cause mortality is unclear. The purpose of this study was to determine the extent to which baseline blood n-3 FA levels are associated with reduced risk for all-cause mortality in patients with stable coronary heart disease. METHODS AND RESULTS: The Heart and Soul study used a prospective cohort design with a median follow-up of 5.9 years. Patients were recruited between 2000 and 2002 from 12 outpatient facilities in the San Francisco Bay Area. Standard cardiovascular risk factors, demographics, socioeconomic status, health behaviors, and inflammatory markers were collected at baseline. Fasting blood levels of eicosapentaenoic and docosahexaenoic acids were measured and expressed as a percent of total blood FAs. Vital status was assessed with annual telephone interviews and confirmed by review of death certificates. There were 237 deaths among 956 patients. Cox proportional hazards models were used to evaluate the extent to which blood eicosapentaenoic and docosahexaenoic acids were independently associated with all cause mortality. Compared with patients having baseline eicosapentaenoic and docosahexaenoic acids levels below the median (<3.6%), those at or above the median had a 27% decreased risk of death (hazard ratio, 0.73; 95% confidence interval, 0.56-0.94). This association was unaffected by adjustment for age, sex, ethnicity, center, socioeconomic status, traditional cardiovascular risk factors, and inflammatory markers (hazard ratio, 0.74; 95% confidence interval, 0.55-1.00, P<0.05). CONCLUSIONS: In these outpatients with stable coronary heart disease, blood n-3 FA levels were inversely associated with total mortality independent of standard and emerging risk factors, suggesting that reduced tissue n-3 FA levels may adversely impact metabolism.
BACKGROUND:Omega-3 fatty acid (n-3 FA) blood levels and intake have been inversely associated with risk for sudden cardiac death, but their relationship with all-cause mortality is unclear. The purpose of this study was to determine the extent to which baseline blood n-3 FA levels are associated with reduced risk for all-cause mortality in patients with stable coronary heart disease. METHODS AND RESULTS: The Heart and Soul study used a prospective cohort design with a median follow-up of 5.9 years. Patients were recruited between 2000 and 2002 from 12 outpatient facilities in the San Francisco Bay Area. Standard cardiovascular risk factors, demographics, socioeconomic status, health behaviors, and inflammatory markers were collected at baseline. Fasting blood levels of eicosapentaenoic and docosahexaenoic acids were measured and expressed as a percent of total blood FAs. Vital status was assessed with annual telephone interviews and confirmed by review of death certificates. There were 237 deaths among 956 patients. Cox proportional hazards models were used to evaluate the extent to which blood eicosapentaenoic and docosahexaenoic acids were independently associated with all cause mortality. Compared with patients having baseline eicosapentaenoic and docosahexaenoic acids levels below the median (<3.6%), those at or above the median had a 27% decreased risk of death (hazard ratio, 0.73; 95% confidence interval, 0.56-0.94). This association was unaffected by adjustment for age, sex, ethnicity, center, socioeconomic status, traditional cardiovascular risk factors, and inflammatory markers (hazard ratio, 0.74; 95% confidence interval, 0.55-1.00, P<0.05). CONCLUSIONS: In these outpatients with stable coronary heart disease, blood n-3 FA levels were inversely associated with total mortality independent of standard and emerging risk factors, suggesting that reduced tissue n-3 FA levels may adversely impact metabolism.
Authors: Roberto Marchioli; Federica Barzi; Elena Bomba; Carmine Chieffo; Domenico Di Gregorio; Rocco Di Mascio; Maria Grazia Franzosi; Enrico Geraci; Giacomo Levantesi; Aldo Pietro Maggioni; Loredana Mantini; Rosa Maria Marfisi; G Mastrogiuseppe; Nicola Mininni; Gian Luigi Nicolosi; Massimo Santini; Carlo Schweiger; Luigi Tavazzi; Gianni Tognoni; Corrado Tucci; Franco Valagussa Journal: Circulation Date: 2002-04-23 Impact factor: 29.690
Authors: Ramin Farzaneh-Far; Jue Lin; Elissa S Epel; William S Harris; Elizabeth H Blackburn; Mary A Whooley Journal: JAMA Date: 2010-01-20 Impact factor: 56.272
Authors: Gregory M Marcus; Mary A Whooley; David V Glidden; Ludmila Pawlikowska; Jonathan G Zaroff; Jeffrey E Olgin Journal: Am Heart J Date: 2007-10-25 Impact factor: 4.749
Authors: Mark K Larson; Joseph H Ashmore; Kristina A Harris; Jessica L Vogelaar; James V Pottala; Michael Sprehe; William S Harris Journal: Thromb Haemost Date: 2008-10 Impact factor: 5.249
Authors: William S Harris; James V Pottala; Sean M Lacey; Ramachandran S Vasan; Martin G Larson; Sander J Robins Journal: Atherosclerosis Date: 2012-06-07 Impact factor: 5.162
Authors: Joel L Ramirez; Greg J Zahner; Kimberly A Spaulding; Sukaynah A Khetani; Nancy K Hills; Warren J Gasper; William S Harris; Beth E Cohen; S Marlene Grenon Journal: Lipids Date: 2019-03-18 Impact factor: 1.880
Authors: William S Harris; James V Pottala; Ramachandran S Vasan; Martin G Larson; Sander J Robins Journal: J Nutr Date: 2012-05-23 Impact factor: 4.798
Authors: Dariush Mozaffarian; Rozenn N Lemaitre; Irena B King; Xiaoling Song; Hongyan Huang; Frank M Sacks; Eric B Rimm; Molin Wang; David S Siscovick Journal: Ann Intern Med Date: 2013-04-02 Impact factor: 25.391